Clinical Trial Update: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial assessing adding apalutamide to radiotherapy and LHRH agonist in high-risk hormone-sensitive prostate cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer
• Prostatic Neoplasms

Drugs mentioned

• Apalutamide (apalutamide)

Snippet

Sponsor: Janssen Pharmaceutica N.V., Belgium | Conditions: Prostatic Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING